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Abstract
Some unique subclasses of Camelidae antibodies are devoid of light chain and the antigen binding
site is comprised exclusively of the variable domain of the heavy chain (VHH). Although
conventional antibodies dominate current assay development, recombinant VHHs have a high
potential as alternative reagents for the next generation of immunoassay. We expressed VHHs
from an immunized alpaca and developed a VHH-based immunoassay using 3-phenoxybenzoic
acid (3-PBA), a major metabolite of pyrethroid insecticides as a model system. A phage VHH
library was constructed and seven VHH clones were selected by competitive binding with 3-PBA.
The best immunoassay developed with one of these VHHs showed an IC50 of 1.4 ng/mL (limit of
detection (LOD) = 0.1 ng/mL). These parameters were further improved by using the phage borne
VHH, IC50 = 0.1 ng/mL and LOD = 0.01 ng/mL. Both assays showed a similar tolerance to
methanol and dimethylsulfoxide up to 50% in assay buffer. The assay was highly specific to 3-
PBA and its 4-hydroxylated derivative, 4-hydroxy 3-PBA (150% cross reactivity) with negligible
cross reactivity with other tested structural analogs and the recovery from spiked urine sample
ranged from 80 to 112%. In conclusion, a highly specific and sensitive VHH for 3-PBA was
developed using sequences from immunized alpaca and phage display technology for antibody
selection.
INTRODUCTION
Since the first radioimmunoassay was reported1, countless immunoassays have been
developed and proven to be invaluable analytical methods for in vitro diagnostics and
environmental monitoring for wide array of substances such as viruses, bacteria, disease
biomarkers, food toxins, and environmental pollutants including endocrine disruptors and
pesticides and their metabolites2–6. For an immunoassay to be applied to a real sample, it
should have high sensitivity and robustness in the matrix in which it is detected. These
properties are largely dependent on the availability of antibodies with high affinity and
specificity to their target analyte along with a high stability in the matrix. Monoclonal
antibodies (MAbs) mostly derived from murine hybridoma cell lines, along with polyclonal
antibodies (PAbs) from sera of rabbits, goats, sheep, and other species are traditional
reagents used in immunoanalytical techniques.
Conventional antibodies (IgG subclass) have an average molecular weight of 150 kDa, and
they are composed of two identical heavy and light chains connected by disulfide bonds.
Each antibody contains two antigen binding pockets. Although PAbs can be easily obtained
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at a low production cost, they are finite, which requires subsequent antibody characterization
and assay optimization because of animal to animal variation in immune response. This can
be a limiting factor for the use of PAbs in development of an assay for large scale
production or commercialization. MAbs obtained from hybridoma cell lines can overcome
the reproducibility issues of PAbs. An established hybridoma can produce MAb indefinitely.
However MAb technology is expensive, sometimes frozen hybridoma cell lines are hard to
recover and generation of high quality MAbs to small molecules is difficult. Because of the
size, the requirement for two chains, and sophisticated post-translational modification,
functional conventional antibodies are difficult to express recombinantly. Many antibody-
derived proteins that are derivatives of an intact antibody molecule have been developed,
including monovalent fragments such as Fab, scFv and engineered variants including
diabodies, triabodies, minibodies, and single-domain antibodies7–9. However, these
constructs often have lower affinity and are less stable than the intact antibody. Production
can be problematic because the limited solubility and aggregation of the expressed antibody
fragments can reduce yields of expressed proteins10, 11. In addition, the diversity of phage
antibody libraries from hybridoma cell lines should be very large to increase the possibility
of selecting a desirable antibody fragment due to the high level of non-functional association
of VHs and VLs12.
In 1993, Hamers-Casterman discovered a new subclass of antibodies in members of the
Camelidae family (i.e. camels, llamas, and alpacas) that have an antigen binding pocket
comprised solely of a variable region of the heavy chain and completely devoid of light
chains13, 14. Recombinant expression of these heavy chain variable domains yields single
domain antibodies (VHHs). The single domain nature of VHHs provides many advantages
over the other recombinant antibody fragments; in particular, ease of expression in various
expression systems, high thermal stability, excellent solubility, resistance to proteolysis, and
ease of genetic manipulation15–17. Antigen-binding patterns of VHHs are very unique
compared to conventional antibodies. Since the binding area of a conventional antibody is
comprised of a heavy chain and a light chain, they tend to bind to proteins through a large
surface area, and they encompass small molecules in a deep cleft formed at an interface of a
heavy and a light chain. Because heavy chain antibodies need to compensate for the missing
light chain, their complementary determining region 3 (CDR3) is normally longer, which
allows the formation of a `finger-like' shape and subsequent binding in a groove of the
protein target18. This allows for heavy chain antibodies to be used as enzyme inhibitors19.
When binding to small molecules, their binding occurs through a lateral recognition
involving the coordinated contribution of the three hyper variable loops and the framework
regions (FRs)20–22. It has also been observed that the binding of a VHH against caffeine is
accompanied by a hapten-induced dimerization of the VHHs23.
To date, most reports about biotechnological applications of VHHs are related to protein or
other macromolecular antigens23, 24, while few reports refer to small-molecules. Some
VHH-based assays have been developed for the detection of small haptens, but, with the
exception of two VHHs against azo-dye Reactive Red20 and ochratoxin A26, the μM range
sensitivities of the assays are somewhat unsatisfactory for practical application to real
samples27–32. We recently demonstrated that the generation of VHHs to triclocarban (TCC)
is not favored in the llama immune response, but that high-affinity anti-TCC VHHs can be
isolated by competitive selection from phage libraries33. The VHH-based ELISA showed
IC50 value of 3.5 ng/mL. To further test this hypothesis and evaluate the potential of VHHs
for the development of practical applications, we present in this work the isolation of alpaca
VHHs to 3-phenoxybenzoic acid (3-PBA) (MW=214), and their use in the immunodetection
of this compound in human urine samples. 3-PBA is a human urinary metabolite of
pyrethroid insecticides and can be used as a biomarker to monitor human exposure to these
pesticides. We have previously developed a PAb-based enzyme-linked immuosorbent assay
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(ELISA) for 3-PBA with IC50 values of 120 ng/mL for a homologous ELISA and 1.6 ng/mL
for a heterologous ELISA34. The same antigen was used in this study to immunize alpacas,
and the VHHs were isolated from a library prepared from their peripheral blood
lymphocytes, leading to the develop of immunoassays to 3-PBA with equal sensitivity than
that obtained with conventional PAbs and excellent recoveries in real samples. Since VHHs
can be produced easily and without the batch-to-batch variations of PAbs, the demonstration
of their high profile performance in a practical application is an important contribution to the
immunoassay technology for small molecules.
EXPERIMENTAL SECTION
A three-year old castrated male alpaca was immunized subcutaneously with 200 μg of 3-
PBA hapten-thyroglobulin conjugate mixed with Freund's incomplete adjuvant. The
immunization, homologous, and heterologous coating antigens were previously synthesized
in this laboratory34 and their structures are presented in figure S-1, supporting information.
Total RNA was extracted from peripheral blood lymphocytes isolated from alpaca blood and
then used for first strand cDNA synthesis. The phage-VHH library was constructed by
cloning PCR amplified VHH genes into the pComb3XSS phagemid vector. Phage anti-3-
PBA VHHs were selected using gradually decreasing concentrations of 3-PBA hapten-BSA
conjugate and free 3-PBA and more stringent washing. Phage VHH clones that show
inhibitory binding to a coating antigen by free 3-PBA were sequenced and soluble VHH
fragments was expressed from TOP10F' cells of E. coli transformed with phagemids
extracted from clones with unique sequences. ELISAs with isolated phage-VHHs
(PELISAs) and soluble VHHs (VELISAs) were used to determine assay sensitivity. The
phage-VHH and VHH with the highest sensitivity were further used for the estimation of
cross-reactivity and assay validation using human urine samples. For more detailed
experimental description, see the supporting information.
RESULTS
Library construction and selection of 3-PBA specific VHHs
The total RNA was extracted from alpaca blood with the leukoLOCK total RNA isolation
system (Applied Biosystems, Foster City, CA) following manufacturer's protocols. VHH
genes were obtained by PCR using a set of sense primers specific for the 5' region of the
heavy chain variable genes paired with a reverse primer specific for either long (IgG2) or
short (IgG3) hinge regions. The amplified genes were cloned into the phagemid vector
pComb3XSS, which was then electroporated into electrocompetent ER2738 cells from E.
coli in order to construct the phage VHH library. The size of the phage VHH library was
3.4×107 colony forming units (c.f.u)/mL.
Figure 1 presents the number of phage output in each panning. The number of phage output
decreased after every round of panning except for the second. Over all there was a 10,000-
fold decrease in the phage output over 5 panning cycles. The 4th and 5th phage outputs were
used to identify positive phage VHH clones for analysis of 3-PBA. Although the number of
phage output decreased with decreasing concentrations of the coating antigen and 3-PBA,
we observed that 100% of tested clones showed different degrees of binding inhibition by
free 3-PBA (data not shown). This result indicates that our panning scheme was very
effective in isolating positive VHH clones. We devised a panning strategy that increased the
selection pressure throughout the panning and minimized the carryover of nonspecific
binders to a next round of panning; preventing the non specific binders from outnumbering
the specific ones. We performed five cycles of panning with modulation of the concentration
of the 3-PBA hapten-BSA conjugate for capturing phage-VHHs, the washing intensity, the
concentration of 3-PBA for the competitive elution of the captured phage-VHHs, and the
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post absorption of phage eluate to BSA. To capture high affinity phage-VHHs to the coating
antigens, the concentration of the coating antigen (0.5, 0.25, 0.1, 0.02, and 0.01 μg per well
over the panning) was gradually decreased. We also decreased the concentration of 3-PBA
by ten-fold for each subsequent round of panning, to elute phage-VHHs with high affinity to
the 3-PBA. To remove non-specific and weakly binding phages we increased the washing
intensity in each round of panning, the phage-VHH captured wells were washed five times
for the 1st panning and washed ten times for the 2nd panning with PBS containing 0.05%
Tween 20 before the competitive elution. For the rest of the pannings, the wells were
washed ten times and then the plates were shaken for 30 min while the wells were filled with
PBS containing 0.1% Tween 20, which was followed by ten more washings. Non-specific
phages were minimized by increasingly stringent washings and post absorption of phage
output to BSA.
Sequence alignment of antibody fragments to 3-PBA
Sixteen clones after the 4th round of panning and 25 clones from the 5th round of panning
that showed an inhibition of binding to the coating antigen by free 3-PBA were sequenced.
Three and 4 unique sequences were found from 4th and 5th round of panning, respectively
(Figure S-2, supporting information). The main features of heavy chain antibodies that
distinguish them from the variable heavy chain domains of conventional IgGs are the
occurrence of amino acids, F, E, R and F/G in the FR2, which stabilize the VHH fragments
and the extended length of CDR3 regions (15–22 amino acids). The amino acid sequences of
the alpaca VHH clones in the region are in agreement with the findings. The deduced amino
acid sequences of the VHH clones show these amino acids in FR2. Clone 3P5ThC19 and
3P5ThC15 have G and P in the region instead of E and G. All clones show 18 amino acids
in the CDR3 region with no significant amino acid variation.
Competitive ELISA for 3-PBA
The sensitivities of assays were estimated by performing an indirect competitive ELISA
with the soluble VHH fragments (Figure 2). The VHHs were expressed from TOP10F' cells
transformed with each phagemid vector isolated from positive clones. The TOP10F' is a
non-suppressor strain, allowing expression of VHHs without the phage pIII protein. The
VHH fragments with 6xHis and HA tags were obtained by purifying cell lysates on the Ni-
NTA affinity columns. The size of purified VHHs was determined on a 12% SDS PAGE gel
as 17 kDa major bands (data not shown). Prior to the indirect ELISA, the optimization of the
coating antigen (3-PBA hapten-BSA) and VHH concentrations were determined by a
checker board titration. As Figure 2 shows, the lowest IC50 value (1.4 ng/mL, 0.007 μM)
was observed from clone 3P5ThC12 which was isolated after the 5th round of panning. The
clone 3P5ThC1 showed a higher IC50 value of 22.8 ng/mL (0.1 μM). Other clones showed
similar IC50 values ranged from 8.2 to 15.7 ng/mL (0.04–0.07 μM). Comparing the
sensitivity of the VHH-based ELISA (VELISA) with the clone 3P5ThC12 to that of our
previously developed PAb-based 3-PBA ELISA, the VELISA is 100-fold more sensitive
than the homologous coating antigen-based ELISA (IC50 of 120 ng/mL) and almost
identical to the best heterologous coating antigen-based ELISA (IC50 of 1.6 ng/mL).
Previously, we increased the sensitivity of the PAb 3-PBA ELISA by use of 3-PBA-BSA
heterologous coating antigen by conjugation using the carboxylic acid moiety. We tested if
this approach would also increase the sensitivity of the VELISA; however, the VHH showed
no recognition to the heterologous coating antigen, indicating that the acid moiety plays a
critical role in the binding of the VHH to the 3-PBA. The ELISA using the VHH from
3P5ThC12 clone has at least a several hundred-fold better sensitivities than the most other
camelid VHH-based ELISAs reported in literature. Therefore, the VHHs and phage-VHHs
derived from 3P5ThC12 clone were used throughout the study.
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Cross-reactivity
The specificity of the assay was tested for the clone 3P5ThC12, which exhibited the best
IC50 value, using four known pyrethroid metabolites and five pyrethroid parent compounds
(Figure 3). The cross-reactivity was determined using the formula, IC50 of 3-PBA ÷ IC50s of
cross-reacting compounds × 100. Overall, negligible cross reactivity was observed, except
for 4'-hydroxy 3-PBA which showed 150% cross reactivity. Since the immunizing hapten
was prepared with the linker attached to –OH group of the 4'-hydroxy-3-PBA, this indicates
that the VHH has some interaction with this oxygen atom.
Phage-VHH ELISA (PELISA)
The M13 bacteriophage is a filamentous virus with a diameter of 6 nm and length of 0.9 μm
containing single strained DNA packed with around 2700 major and several minor coat
proteins. When a VHH fragment possesses a good binding affinity, an assay using the phage
displayed-VHH can provide advantages over a monomeric soluble expressed VHH
fragment. First, the phage can improve assay sensitivity by using it as a multiple binding
element, secondly, the phage particle is also adaptable to various detection methods such as
immuno-PCR36, 37, and numerous types of biosensors38. Another advantage of the PELISA
is that phage-VHH can be easily and inexpensively prepared in high concentrations. Phage-
VHH expressed in a culture medium can be readily isolated by simple incubation and
centrifugation, eliminating laborious procedures such as cell lysis and Ni-NTA purification
necessary for the expression of soluble VHH fragments. Goldman et al.39, 40 evaluated the
utility of phage-VHHs derived from llama for ricin and botulinum A employing a sandwich
ELISA and Luminex technology. They observed one to two orders of magnitude of
sensitivity improvement compared to a standard ELISA with soluble VHHs.
We also evaluated the performance of the PELISA using the phage-displayed VHH of the
clone 3P5ThC12 in an indirect competitive ELISA format (Figure 4). The checkerboard
titration was used to determine the optimal concentrations of the coating antigen and the
phage-VHH using two blocking reagents (1% BSA and 3% skim milk in PBS). As shown in
the figure, when the plate was blocked with 1% BSA, the IC50 value was 0.6 ng/mL,
showing slightly enhanced sensitivity compared to the VELISA. However, we observed a 6-
fold improvement of the assay sensitivity when 3% of skim milk was used for blocking with
an IC50 of 0.1 ng/mL which is 10-fold better than the VELISA. To generate a similar
maximal signal to the VELISA, the PELISA required the use of coating antigen at 0.4 μg/
mL which is 8-fold higher than the concentration for the VELISA. We tested the VELISA
using a plate blocked with 3% skim milk, the assay sensitivity was similarly enhanced, but
signal variations among replicates were significantly higher (data not shown). Thus, we used
1% BSA blocking for the VELISA.
Solvent effect
High tolerance to solvents is beneficial when developing immunoassays to be used for
analysis of lipophilic analytes, because water miscible solvents are commonly used for
extraction of analyte prior to analysis. When the matrix effects for solvent extracts are
negligible less dilution of the extracts is needed, which results in enhanced assay sensitivity.
Although the camelid VHHs have been known to be highly thermally stable, no evaluation
has been done for the tolerance of VHHs or phage-displayed VHHs to such water miscible
solvents. Hence, we estimated the effect of methanol (MeOH) and dimethylsulfoxide
(DMSO) on the performance of the VELISA and PELISA and compared to that of the PAb-
based 3-PBA ELISA. Each solvent was added to the assay buffer at concentrations of 0, 10,
25 and 50% (v/v), while maintaining constant ionic strength. Figure 5 presents the MeOH
effects on the assay performance. Typically, increasing the concentration of MeOH in
ELISAs causes an increase in both the maximal signal and the IC50 values. All assays
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showed the increase of the maximal signals likewise when the MeOH concentrations
increased with more significant increase in the PELISA. Interestingly, the assay sensitivity
also was improved for the VELISA and PELISA, which indicates that the addition of MeOH
facilitates the binding interaction with minimal effect on the protein function. However, the
MeOH showed a more significant effect on the sensitivity of the 3-PBA ELISA showing a
small but gradual increase of IC50 values. A four-fold increase in IC50 value was observed at
50% (v/v) of MeOH. This result demonstrated that both the VHH and phage-VHH were
highly tolerant to MeOH.
DMSO did not affect the binding of the VHH and the phage-VHH, because IC50 values
changed insignificantly in the presence of up to 50% (v/v) of DMSO (Figure 6). In contrast,
DMSO had a significant effect in the PAb 3-PBA ELISA causing 50% reduction in maximal
signal at 50% (v/v) DMSO with slight increase of IC50s. The above results demonstrate that
the VHH and phage-VHH are more tolerant to solvent effect than the PAb ELISA.
Assay validation
The VELISA and PELISA were validated using a urine sample collected from a person with
no known exposure to pyrethroid insecticides. The urine was spiked with 3-PBA at 5
different concentrations. The spiked urine samples were diluted with PBS buffer to a final
concentration of urine of 4%. An aliquot of the diluted urine samples was mixed with an
equal volume of the VHH or phage-VHH diluted in PBS for competition (Figure 7). The
matrix effect test revealed that the urine content in the assay buffer should be less than 2% to
remove the matrix interference on the assay (data not shown). In general, both assays
showed good correlations between the spiked and recovered concentrations with an average
recovery of 80–110%. We also observed minor false positive detection from urine with no
3-PBA. It should be noted that although the dilution of urine samples can be used for the
analysis of urine containing concentrations of 3-PBA higher than 100 ng/mL, sample
preparation by solid-phase extraction (SPE) or a mixed-mode SPE method is necessary to
detect low concentrations of 3-PBA and for more accurate determination in urine samples41.
For this, the urine sample was spiked with four low concentrations of 3-PBA (1, 5, 20, and
50 ng/mL) and the analytes were extracted by the mixed-mode SPE method. The recoveries
by the VELISA were compared to the recoveries by a gas-chromatography mass
spectrometry (GC-MS). We observed an excellent correlation between two methods with
VELISA recoveries of 82–110% (Table S-1, supporting information).
CONCLUSION
In this case we were able to obtain a homologous VELISA and PELISA that were of equal
or greater sensitivity to our best PAb-based heterologous assay for the development of a
sensitive assay for 3-PBA using alpaca VHH and phage-VHH fragments. We demonstrated
that the alpaca is a good source for the VHH recombinant antibodies leading to small
molecular weight compounds. The assays using the VHH and phage-VHH derived from
clone 3P5ThC12 showed several hundred times better sensitivity than other assays that have
been developed using camelid VHHs for small molecules. This observation indicates that a
good panning strategy can be very effective in isolating a high affinity VHH for small
haptens starting with alpaca RNA. The sensitivity of the VELISA and PELISA with the
homologous coating antigen was approximately 80- and 1200-fold better than the
homologous 3-PBA ELISA, respectively. The VELISA showed almost identical sensitivity
to our best heterologous ELISA, but 10-fold better sensitivity was observed from the
PELISA. Although monoclonal type VHH showed a similar sensitivity to the 3-PBA
heterologous assay, the use of heterologous antigens with linkers attached to –OH moiety of
the 3-PBA hapten may further improve assay sensitivity. The VHH and phage-VHH showed
higher tolerance to MeOH and DMSO than the PAb. The size of a VHH is one tenth of
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conventional antibodies, and it is much more robust than MAbs and PAbs with high
resistance to heat and solvent effects. The size and robustness of the VHH is a significant
advantage when developing assays or biosensors, because the stability and the small size
allow them to be immobilized on a miniaturized sensor chip in higher density and leads to a
longer shelf life of the assay. This feature is particularly significant for field use diagnostics
where refrigeration is often limited, solvent-based sample preparation conditions are
required, and sample cleanup procedures must be simple. Since the phage-VHH retain the
stability and affinity of the VHH, the phage particles are very robust and serve as a multi-
binding scaffold for signal enhancement, which increased the sensitivity as we have
demonstrated. The phage-VHH was easily obtained by simple procedures. The VELISA and
PELISA both showed good recovery of spiked samples in a urine matrix with an average
recovery of 80–110%. The dilution of urine sample can be used for urine containing
relatively high concentrations of 3-PBA, if more sensitivity is needed samples would have to
be extracted prior to analysis. Sample pretreatment by the simple mixed-mode SPE allowed
the detection of 3-PBA at very low concentrations. As we have demonstrated here, camelid
VHHs will be a useful tool in the future of small molecule immunoassays.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Number of phage output. Ten μl of the phage output were diluted in a sterile PBS from each
panning cycle and were mixed with 1ml of ER2738 cells with absorbance of 0.4 at O.D600.
The mixture was incubated for 25 min at 37 °C without shaking. The mixture was plated on
a LB-plate with ampicillin. The number of colonies was counted the following day.
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Figure 2.
Competition ELISA with soluble VHHs. Representative curves showing the inhibition of
VHH clones binding to 3-PBA hapten-BSA with increasing amount of the free 3-PBA. 3-
PBA hapten-BSA was immobilized and competition mixture was added. After washing,
bound VHH was detected with goat anti-HA tag PAb-HRP. Data are represented as an
average +/− standard deviation of four replicates.
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Figure 3.
Cross reactivity. The 96 well plates were coated with 3-PBA hapten-BSA conjugate at 5 ng/
well. Serial dilutions of 3-PBA or tested compounds in PBS were mixed with an equal
amount of 1/1000 dilution of the VHH in PBS. One hundred μl of the mixture was added
into wells. The bound VHH was detected with 1/10000 dilution of goat anti-HA tag PAb-
HRP.
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Figure 4.
Competitive binding of the phage-VHH. A 96-well plate was coated with 3-PBA hapten-
BSA conjugate at 0.4 μg/mL. Dilutions of 3-PBA in PBS was mixed with a 1/2500 dilution
of the phage-VHH in PBS and 100 μl of the mixture was added into wells. The bound
phage-VHHs were detected by adding 100 μl of mouse anti-M13 phage MAb-HRP diluted
in PBS at 1/5000.
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Figure 5.
Effects of MeOH on the performance of the VELISA (A), PELISA (B), and 3-PBA ELISA
(C). PBS buffers containing MeOH at different concentrations were used to make serial
dilutions of 3-PBA. The serial dilutions were mixed with an equal volume of VHH, phage-
VHH, or 3-PBA PAb and then 100 μL of the mixture was added into wells. The bound
immunoreagents were detected by adding 100 μL of goat anti-HA tag PAb, mouse anti-M13
phage MAb, and goat anti-rabbit PAb conjugated with HRP, respectively. Values are the
mean +/− standard deviation of 4 well replicates.
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Figure 6.
Effects of DMSO on the performance of the VELISA (A), PELISA (B), and 3-PBA ELISA
(C). PBS buffers containing DMSO at different concentrations were used to make serial
dilutions of 3-PBA. The serial dilutions were mixed with an equal volume of VHH, phage-
VHH, or 3-PBA PAb and then 100 μl of the mixture was added into wells. The bound
immunoreagents were detected by adding 100 μl of goat anti-HA tag PAb, mouse anti-M13
phage MAb, and goat anti-rabbit PAb conjugated with HRP, respectively. Values are the
mean +/− standard deviation of 4 well replicates.
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Figure 7.
The validation of the VELISA and PELISA in a urine matrix. 3-PBA standard compound
was spiked into the urine sample before it was diluted 25-fold with PBS buffer. The
dilutions of 3-PBA spiked urine were mixed with an equal volume of VHH or phage-VHH
diluted in PBS before analysis.
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